OpenAI and Novo Nordisk Team Up for Drug Discovery

OpenAI has partnered with pharmaceutical giant Novo Nordisk to embed AI agents across its drug discovery, manufacturing, and distribution workflows. The collaboration will give Novo Nordisk access to OpenAI's most advanced models to analyze genomic, biological, and clinical trial datasets at unprecedented scale. The partnership aims to shorten lengthy drug development cycles by simulating lab experiments and predicting drug efficacy before physical testing. OpenAI will also train Novo Nordisk employees to build custom AI tools. Pilot programs will begin immediately, with full global integration targeted by year's end.